Birk Venture
Birk Venture is a venture capital firm based in Oslo, Norway, founded in 2010. The firm specializes in early-stage investments within the life science industry, focusing on sectors such as pharmaceuticals, biotechnology, diagnostics, medical devices, and consumer health. Birk Venture targets small-sized and start-up companies that possess unique technologies and the potential for significant growth. Additionally, the firm is open to co-investing with other firms to secure necessary capital. Birk Venture is interested in both public and private companies, particularly those that may become publicly listed within one to two years.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Norway
Zelluna Immunotherapy
Seed Round in 2017
Zelluna Immunotherapy is a Norwegian biopharmaceutical company focused on developing T-cell receptor based cancer immunotherapies. Founded in 2016 and based in Oslo, it pursues a pipeline of tumor-specific TCRs, many derived from patients who showed long-term survival after peptide-based cancer vaccine trials at the Norwegian Radium Hospital/Oslo University Hospital. The company aims to enable immune cells to recognize a broad range of cancers with safety and durability. It operates in collaboration with Oslo Cancer Cluster and is located at the Oslo Cancer Cluster Innovation Park near major hospital facilities and GMP-certified cellular therapy capabilities.
APIM Therapeutics
Venture Round in 2012
APIM Therapeutics develops innovative peptide drugs targeting Proliferating Cell Nuclear Antigen (PCNA), a key protein regulating cellular responses to DNA damage and stress in cancer cells. Founded on groundbreaking research from NTNU, Trondheim, Norway, the company aims to eliminate and cure cancer-specific tumor cells.
APIM Therapeutics
Venture Round in 2011
APIM Therapeutics develops innovative peptide drugs targeting Proliferating Cell Nuclear Antigen (PCNA), a key protein regulating cellular responses to DNA damage and stress in cancer cells. Founded on groundbreaking research from NTNU, Trondheim, Norway, the company aims to eliminate and cure cancer-specific tumor cells.
Nordic Nanovector
Seed Round in 2010
Nordic Nanovector is a biopharmaceutical company focused on developing innovative therapeutics for haematological cancers. Its lead product, Betalutin, an antibody-radionuclide-conjugate, is in clinical trials for treating non-Hodgkin lymphoma. The company aims to commercialize its products while building a pipeline of novel therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.